(NASDAQ: ELTX) Elicio Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 43.76%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.6%.
Elicio Therapeutics's earnings in 2025 is -$45,857,000.On average, 4 Wall Street analysts forecast ELTX's earnings for 2025 to be -$44,687,462, with the lowest ELTX earnings forecast at -$43,534,903, and the highest ELTX earnings forecast at -$45,359,060. On average, 4 Wall Street analysts forecast ELTX's earnings for 2026 to be -$26,848,156, with the lowest ELTX earnings forecast at -$29,480,328, and the highest ELTX earnings forecast at -$23,689,549.
In 2027, ELTX is forecast to generate -$24,975,029 in earnings, with the lowest earnings forecast at -$23,995,616 and the highest earnings forecast at -$25,709,589.